ArticleActa oncologica (Stockholm, Sweden)2025
Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?Acta oncologica (Stockholm, Sweden) · 2026Trial
- A controlled trial comparing dosimetry and radiation pneumonitis between tomotherapy and IMRT in patients with lung or esophageal cancer.Journal of applied clinical medical physics · 2026Trial
- Article
- Article
- Clinical validation of a high-definition mid-position magnetic resonance imaging approach for lung radiotherapy planning.Medical physics · 2026Article
- Radiation-induced lung injury in the era of combination anticancer therapy: a narrative review.Frontiers in immunology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAdding adjuvant durvalumab to chemoradiotherapy (CRT) improves overall survival (OS) rates in locally advanced Non-Small-Cell Lung Cancer (NSCLC). However, recent data suggests that this new modality increases the incidence of radiation pneumonitis (RP). The aim of this study was to test the hypothesis that the incidence of RP after CRT and adjuvant durvalumab was higher than after CRT alone among patients with locally advanced NSCLC. MATERIALS AND
methodsThe study population comprised all patients with NSCLC who completed CRT with curative intent between February 2013 and October 2020. From 2018 on, adjuvant durvalumab was administered in selected patients after completion of CRT. Patient and treatment data together with RP data (CTCAEv4.0, scored up to 9 months after CRT), were prospectively collected as part of our standard follow-up program.
resultsA total of 284 patients were included, of which 90 (30.5%) received adjuvant durvalumab. Incidence of grade ≥2 RP increased in patients receiving durvalumab compared to CRT only (17.8% vs. 8.8%; p < 0.05), especially between 6 to 9 months after completing CRT. Adjuvant durvalumab and mean lung dose (MLD) were associated with a higher incidence of grade ≥2 RP (odds ratio [OR]: 2.43 and 1.14, respectively; p < 0.05). Current smoking was found to be a protective factor (OR: 0.38; p < 0.05).
interpretationAdjuvant durvalumab significantly increased the incidence of grade ≥2 RP in this real-world cohort of NSCLC patients. Patients receiving adjuvant durvalumab remain prone to develop grade ≥2 RP longer after completing CRT compared to patients treated with CRT only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.